Detection of Malignant Melanoma Using Artificial Intelligence: An Observational Study of Diagnostic Accuracy
- PMID: 31921498
- PMCID: PMC6936633
- DOI: 10.5826/dpc.1001a11
Detection of Malignant Melanoma Using Artificial Intelligence: An Observational Study of Diagnostic Accuracy
Abstract
Background: Malignant melanoma can most successfully be cured when diagnosed at an early stage in the natural history. However, there is controversy over screening programs and many advocate screening only for high-risk individuals.
Objectives: This study aimed to evaluate the accuracy of an artificial intelligence neural network (Deep Ensemble for Recognition of Melanoma [DERM]) to identify malignant melanoma from dermoscopic images of pigmented skin lesions and to show how this compared to doctors' performance assessed by meta-analysis.
Methods: DERM was trained and tested using 7,102 dermoscopic images of both histologically confirmed melanoma (24%) and benign pigmented lesions (76%). A meta-analysis was conducted of studies examining the accuracy of naked-eye examination, with or without dermoscopy, by specialist and general physicians whose clinical diagnosis was compared to histopathology. The meta-analysis was based on evaluation of 32,226 pigmented lesions including 3,277 histopathology-confirmed malignant melanoma cases. The receiver operating characteristic (ROC) curve was used to examine and compare the diagnostic accuracy.
Results: DERM achieved a ROC area under the curve (AUC) of 0.93 (95% confidence interval: 0.92-0.94), and sensitivity and specificity of 85.0% and 85.3%, respectively. Avoidance of false-negative results is essential, so different decision thresholds were examined. At 95% sensitivity DERM achieved a specificity of 64.1% and at 95% specificity the sensitivity was 67%. The meta-analysis showed primary care physicians (10 studies) achieve an AUC of 0.83 (95% confidence interval: 0.79-0.86), with sensitivity and specificity of 79.9% and 70.9%; and dermatologists (92 studies) 0.91 (0.88-0.93), 87.5%, and 81.4%, respectively.
Conclusions: DERM has the potential to be used as a decision support tool in primary care, by providing dermatologist-grade recommendation on the likelihood of malignant melanoma.
Keywords: artificial intelligence; detection; identification; melanoma; primary care.
Copyright: ©2019 Phillips et al.
Conflict of interest statement
Competing interests: The authors have no conflicts of interest to disclose.
Figures







Similar articles
-
Assessment of Accuracy of an Artificial Intelligence Algorithm to Detect Melanoma in Images of Skin Lesions.JAMA Netw Open. 2019 Oct 2;2(10):e1913436. doi: 10.1001/jamanetworkopen.2019.13436. JAMA Netw Open. 2019. PMID: 31617929 Free PMC article. Clinical Trial.
-
[The Rise of Artificial Intelligence - High Prediction Accuracy in Early Detection of Pigmented Melanoma].Laryngorhinootologie. 2023 Jul;102(7):496-503. doi: 10.1055/a-1949-3639. Epub 2022 Dec 29. Laryngorhinootologie. 2023. PMID: 36580975 German.
-
Diagnostic performance of augmented intelligence with 2D and 3D total body photography and convolutional neural networks in a high-risk population for melanoma under real-world conditions: A new era of skin cancer screening?Eur J Cancer. 2023 Sep;190:112954. doi: 10.1016/j.ejca.2023.112954. Epub 2023 Jun 24. Eur J Cancer. 2023. PMID: 37453242
-
Analysis of Artificial Intelligence-Based Approaches Applied to Non-Invasive Imaging for Early Detection of Melanoma: A Systematic Review.Cancers (Basel). 2023 Sep 23;15(19):4694. doi: 10.3390/cancers15194694. Cancers (Basel). 2023. PMID: 37835388 Free PMC article. Review.
-
Role of In Vivo Reflectance Confocal Microscopy in the Analysis of Melanocytic Lesions.Acta Dermatovenerol Croat. 2018 Apr;26(1):64-67. Acta Dermatovenerol Croat. 2018. PMID: 29782304 Review.
Cited by
-
Molecular Biomarkers for Melanoma Screening, Diagnosis and Prognosis: Current State and Future Prospects.Front Med (Lausanne). 2021 Apr 16;8:642380. doi: 10.3389/fmed.2021.642380. eCollection 2021. Front Med (Lausanne). 2021. PMID: 33937286 Free PMC article. Review.
-
Lack of Transparency and Potential Bias in Artificial Intelligence Data Sets and Algorithms: A Scoping Review.JAMA Dermatol. 2021 Nov 1;157(11):1362-1369. doi: 10.1001/jamadermatol.2021.3129. JAMA Dermatol. 2021. PMID: 34550305 Free PMC article.
-
Disease Prediction Using Machine Learning on Smartphone-Based Eye, Skin, and Voice Data: Scoping Review.JMIR AI. 2025 Mar 25;4:e59094. doi: 10.2196/59094. JMIR AI. 2025. PMID: 40132187 Free PMC article. Review.
-
Prospective multicenter study using artificial intelligence to improve dermoscopic melanoma diagnosis in patient care.Commun Med (Lond). 2024 Sep 11;4(1):177. doi: 10.1038/s43856-024-00598-5. Commun Med (Lond). 2024. PMID: 39256516 Free PMC article.
-
Comprehensive analysis of clinical images contributions for melanoma classification using convolutional neural networks.Skin Res Technol. 2024 May;30(5):e13607. doi: 10.1111/srt.13607. Skin Res Technol. 2024. PMID: 38742379 Free PMC article.
References
-
- Marsden JR, Newton-Bishop JA, Burrows L, et al. Revised U.K. guidelines for the management of cutaneous melanoma 2010. Br J Dermatol. 2010;163(2):238–256. - PubMed
-
- Wernli KJ, Henrikson NB, Morrison CC, Nguyen M, Pocobelli G, Whitlock EP. U.S. Preventive Services Task Force Evidence Syntheses, formerly Systematic Evidence Reviews. Rockville, MD: Agency for Healthcare Research and Quality (US); 2016. Screening for Skin Cancer in Adults: An Updated Systematic Evidence Review for the US Preventive Services Task Force [Internet] - PubMed
-
- National Collaborating Centre for Cancer (UK) National Institute for Health and Care Excellence: Clinical Guidelines. London: National Institute for Health and Care Excellence (UK); 2015. Melanoma: Assessment and Management.
LinkOut - more resources
Full Text Sources